Evaluation of the LSA2L2 protocol for treatment of childhood non-Hodgkinʼs lymphoma

Bogusławska-Jaworska, J; Kościelniak, Ewa; Sroczyńska, M; Sońta-Jakimczyk, D; Armata, J; Balwierz, Walentyna; Ciepielewska, D; Kaczmarek-Kanold, M; Ochocka, M; Radwańska, U

doi:10.1097/00043426-198424000-00002

Cited by 8 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Indications for and benefits of intensive therapies in treatment of childhood cancers

Lampkin

Wong

1986

Cancer

View full text Add to dashboard Cite

There has been a striking improvement in the overall numbers of children and adolescents who become disease-free and remain disease-free as a result of intensive therapy as defined today, for the following cancers: acute nonlymphocytic leukemia (ANLL), non-Hodgkin's lymphoma (NHL), poor risk acute lymphocytic leukemia (ALL), osteosarcoma, and Ewing's sarcoma. The therapy for each of these tumors, with the exception of osteosarcoma, consisted of combination chemotherapy with or without radiotherapy and was started as soon after diagnosis as possible. Aggressive therapy of osteosarcoma has consisted of surgical removal of lung metastases and chemotherapy. Intensive chemotherapy recently has included the use of high doses of certain drugs such as cytosine arabinoside (Ara-C), methotrexate, VP-16-213 and melphalan in the treatment of patients with tumors that are currently difficult to treat.

show abstract

Indications for and benefits of intensive therapies in treatment of childhood cancers

Lampkin

Wong

1986

Cancer

View full text Add to dashboard Cite

show abstract

Factors of prognostic importance in childhood non-hodgkin's lymphoma treated with two modified lsa2-l2 protocols. A multivariate analysis approach

Andrea

Franco

Alves

et al. 1988

Cancer

View full text Add to dashboard Cite

The results of therapy given to 74 children with advanced disease, abdominal non-Hodgkin's lymphoma were retrospectively evaluated with respect to the major prognostic factors related to disease outcome. The first 36 patients admitted in the study were treated with a modified LSA2-L2 protocol, and the remaining patients received the same regimen with the addition of intermediate-dose methotrexate (MTX) intravenously during the induction phase (LSA2-L2-MTX). The last ten patients admitted were given a leucovorin rescue along with the administration of MTX. The relative efficacy of the LSA2-L2-MTX over the baseline LSA2-L2 regimen was analyzed by multivariate statistical methods taking into consideration several candidate coprognostic factors. The risk of treatment failure was substantially reduced (55%) with the use of the LSA2-L2-MTX regimen. Rescue with leucovorin did not contribute a further significant gain in treatment efficacy, although fewer toxicity-related problems were observed as compared to the no-rescue period. Five prognostic factors emerged as significantly explanatory of the risk of treatment failure in addition to protocol type: lymphocyte count, disease stage, surgical debulking, sex, and nutritional status. Based on these variables, a logistic regression equation could be derived to identify groups that were at risk for treatment failure.

show abstract

Progress in Treatment of Children with non-Hodgkin Lymphoma: A Report of the Polish Leukemia and Lymphoma Study Group

et al. 1987

View full text Add to dashboard Cite

Evaluation of the LSA2L2 protocol for treatment of childhood non-Hodgkinʼs lymphoma

Cited by 8 publications

References 0 publications

Indications for and benefits of intensive therapies in treatment of childhood cancers

Indications for and benefits of intensive therapies in treatment of childhood cancers

Factors of prognostic importance in childhood non-hodgkin's lymphoma treated with two modified lsa2-l2 protocols. A multivariate analysis approach

Progress in Treatment of Children with non-Hodgkin Lymphoma: A Report of the Polish Leukemia and Lymphoma Study Group

Contact Info

Product

Resources

About